HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.

AbstractBACKGROUND:
Optimizing iron and recombinant human erythropoietin (rHuEPO) therapy is necessary to achieve target hemoglobin levels and minimize costs as the end-stage renal disease (ESRD) population expands. Oral iron products in patients with ESRD have been largely abandoned, and the safety of intravenous (IV) iron preparations has improved with the introduction of new-generation compounds that have little allergenicity. Recent work suggests oral heme iron may be an effective supplement for hemodialysis (HD) patients because it is absorbed by patients with high ferritin levels, has fewer side effects, and its absorption is stimulated by erythropoietin administration.
METHODS:
We performed an open, 6-month, prospective evaluation of heme iron in HD patients who had been on maintenance IV iron therapy. IV iron was discontinued and replaced with oral heme iron. Serum iron level, hematocrit (Hct), and erythropoietin and IV iron dose were monitored.
RESULTS:
During 6 months, 4 of 37 patients (11%) dropped out because of insufficient iron supplementation or intolerance and 5 patients (14%) were dropped because of unrelated complications or protocol violation. A slight reduction in average transferrin saturation (TSAT) was seen early, but reversed, and no significant changes were seen in TSAT or Hct. A significant reduction in average serum ferritin level was seen at months 4 through 6 (P < 0.01).
CONCLUSION:
During the 6-month study period, heme iron polypeptide successfully replaced IV iron therapy in a majority of HD patients and maintained target Hcts with no concomitant use of IV iron. This treatment was associated with a significant increase in rHuEPO efficiency (P = 0.04).
AuthorsAllen R Nissenson, Jeffrey S Berns, Paul Sakiewicz, Sana Ghaddar, Gary M Moore, Rhoda B Schleicher, Paul A Seligman
JournalAmerican journal of kidney diseases : the official journal of the National Kidney Foundation (Am J Kidney Dis) Vol. 42 Issue 2 Pg. 325-30 (Aug 2003) ISSN: 1523-6838 [Electronic] United States
PMID12900815 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Peptides
  • Recombinant Proteins
  • Tablets
  • Transferrin
  • Erythropoietin
  • Ferritins
  • Iron
Topics
  • Administration, Oral
  • Aged
  • Anemia (drug therapy, etiology)
  • Erythropoietin (administration & dosage, therapeutic use)
  • Female
  • Ferritins (blood)
  • Hematocrit
  • Humans
  • Infusions, Intravenous
  • Iron (administration & dosage, blood)
  • Kidney Failure, Chronic (blood, complications, therapy)
  • Male
  • Middle Aged
  • Peptides (administration & dosage, therapeutic use)
  • Prospective Studies
  • Recombinant Proteins
  • Renal Dialysis
  • Tablets
  • Transferrin (analysis)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: